Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23910877 | 1.00 | PTGDR2 (0.39) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL20765258 | 0.83 | ENPP3 (0.43) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL18376651 | 0.82 | SRC (0.35) | KDM4EALDH1A1GAAPKMHTT | |
| SCHEMBL1154907 | 0.80 | PTGDR2 (0.48) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL29959159 | 0.80 | PTGDR2 (0.48) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL5661951 | 0.76 | ENPP3 (0.44) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL30751165 | 0.76 | ENPP3 (0.44) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL25324645 | 0.76 | ENPP3 (0.44) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL18980291 | 0.75 | PIK3C3 (0.46) | PTGDR2ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL16546218 | 0.75 | PTGDR2 (0.45) | PTGDR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | PTGDR2 4346/4885ENPP3 1611/4885ENPP1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.